Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (Kyprolis®) And Dexamethasone Versus Carfilzomib With Dexamethasone In Patients With Relapse And/Or Refractory Multiple Myeloma Previously Treated With 1 to 3 Prior Lines

NCT03275285 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03275285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03275285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (Kyprolis®) And Dexamethasone Versus Carfilzomib With Dexamethasone In Patients With Relapse And/Or Refractory Multiple Myeloma Previously Treated With 1 to 3 Prior Lines
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
October 25, 2017
Completion date
January 3, 2025
Enrollment
302 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell myeloma